EU pilot project to assess value of new drugs at an early stage
This article was originally published in SRA
The European Medicines Agency and stakeholders from six EU countries have launched a pilot project on assessing the therapeutic and economic value of new drugs at an early stage of their development1.
You may also be interested in...
Despite the life sciences industry’s call for continued alignment of medicines regulation with the EU from next year and for some sort of co-operation with the European Medicines Agency, it seems the UK government is prepared to make only small concessions.
The UK’s decision to pull out of Europe’s Unified Patent Court system throws the future of the whole project into doubt.
As fears grow that a full-blown COVID-19 pandemic may be on the way, a European public-private consortium is to make available a total of €45m (US$49m) in funding for projects aimed at accelerating the development of diagnostics and therapeutics to help tackle the current outbreak and any future coronavirus threats.